Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quick-Med wins new US patent for Nimbus technology
This patent stems from a provisional patent application filed with the US Patent and Trademark Office in February 2004 by Quick-Med. The new patent, together with a previously
This patent stems from a provisional patent application filed with the US Patent and Trademark Office in February 2004 by Quick-Med. The new patent, together with a previously
Highlights for Fourth Quarter and Full Year 2008 Full year 2008 revenue generated in China and international markets up 61.1% and 110.4%, respectively, over 2007 to a total
The agreement grants Pediapharm exclusivity in the territory for the distribution and marketing of EpiCeram while Ceragenix will be responsible for the manufacturing and supply of the product.
For the dry eye clinical trial, EyeGate worked with Ora, a global clinical R&D organization, located in Andover, Massachusetts. This Phase II single-center, randomized, double-masked, placebo-controlled study of
The FDA’s approval follows a similar decision by the Medicines and Healthcare Products Regulatory Agency in February 2009 under which 24 EU member states have mutually recognized an
In addition, the company will issue to the investor warrants to purchase 5.55 million shares of common stock at an exercise price of $1.25 per share. Tony Shum,
According to Boston Scientific, the Taxus Liberte is the only second-generation drug-eluting stent available in Japan. Design improvements over the company’s first-generation Taxus Express2 stent include thinner struts
Mr Gabrielson presently serves on the company’s board of directors and, most recently, was managing general partner of p-Value Capital, a specialty financial services firm. Mr Gabrielson also
According to Flexible Stenting Solutions (FSS), the FlexStent biliary self expanding stent system is indicated for the palliative treatment of biliary strictures resulting from malignant neoplasms. In addition
Smith & Nephew’s Orthopaedics business and BrainLAB have signed an agreement by which BrainLAB will become the exclusive vendor for developing and supporting computer-assisted surgical technologies for Smith